Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Regulus Therapeutics Inc. (NASDAQ: RGLS).

Full DD Report for RGLS

You must become a subscriber to view this report.


Recent News from (NASDAQ: RGLS)

Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global, and MedEquities Realty Trust - Future Expectations, Projections Moving into 2018
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regulus Therapeutics Inc. (NASDAQ:RGLS), Airgain, Inc. (NASDAQ:AIRG), Mich...
Source: GlobeNewswire
Date: May, 17 2018 07:40
Regulus Therapeutics' (RGLS) CEO Joseph Hagan on Q1 2018 Results - Earnings Call Transcript
Regulus Therapeutics Inc. (RGLS) Q1 2018 Earnings Conference Call May 10, 2018 5:00 pm ET Executives Allison Wey - VP, IR and Corporate Communications Joseph Hagan - President and CEO Timothy M. Wright - Chief Research and Development Officer Dan Chevallard - CFO Analysts ...
Source: SeekingAlpha
Date: May, 10 2018 21:27
Regulus Therapeutics EPS and revenue in-line
Regulus Therapeutics (NASDAQ: RGLS ): Q1 EPS of -$0.15 in-line. Revenue of $0.02M in-line (flat Y/Y). Press Release More news on: Regulus Therapeutics, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 10 2018 16:15
Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress
LA JOLLA, Calif. , May 10, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the first quarter ended March 31, 2018 and...
Source: PR Newswire
Date: May, 10 2018 16:10
Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018
LA JOLLA, Calif. , May 3, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide first quarter 2018 financial results and corporate high...
Source: PR Newswire
Date: May, 03 2018 16:15
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
Regulus launches early-stage study of RGLS4326 in inherited kidney cyst disorder; shares up 3%
Regulus Therapeutics ( RGLS +3% ) initiates a Phase 1 multiple ascending dose clinical trial assessing RGLS4326 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), an inherited disorder characterized by the formation of cysts on the kidney that leads to failure. ...
Source: SeekingAlpha
Date: May, 01 2018 11:38
Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD
LA JOLLA, Calif. , May 1, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has initiated a Phase I multiple ascending dose (MAD) study ...
Source: PR Newswire
Date: May, 01 2018 08:30
Kathryn J. Collier Joins Regulus Board of Directors
LA JOLLA, Calif. , April 17, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced Kathryn J. Collier has joined the Company's board of directors....
Source: PR Newswire
Date: April, 17 2018 16:10
Regulus to Present at the Needham Healthcare Conference
LA JOLLA, Calif. , March 20, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regu...
Source: PR Newswire
Date: March, 20 2018 16:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-240.7360.72690.7360.7087,653
2018-05-230.700.70410.720.692998,594
2018-05-220.70990.70020.710.683184,655
2018-05-210.740.700.740110.69136,421
2018-05-180.71550.70930.7393740.7056,637

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2411,67538,58630.2571Cover
2018-05-2314,91042,25935.2824Short
2018-05-2272,800110,99365.5897Short
2018-05-2114,41562,75422.9706Cover
2018-05-188,36530,60527.3321Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RGLS.


About Regulus Therapeutics Inc. (NASDAQ: RGLS)

Logo for Regulus Therapeutics Inc. (NASDAQ: RGLS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: RGLS)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 27 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 20 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 20 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 17 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 22 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 07 2018

       

       


      Daily Technical Chart for (NASDAQ: RGLS)

      Daily Technical Chart for (NASDAQ: RGLS)


      Stay tuned for daily updates and more on (NASDAQ: RGLS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: RGLS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      Monsta Trader
      @MonstaTrader

       

       


      Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RGLS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of RGLS and does not buy, sell, or trade any shares of RGLS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/